Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GSK3901961 |
Synonyms | |
Therapy Description |
GSK3901961 are autologous T lymphocytes engineered to express the CD8-alpha chain and a T-cell receptor targeting NY-ESO-1, which may lead to cytotoxic T-cell-mediated killing of NY-ESO-1-overexpressing tumor cells (J Clin Oncol 39, no. 15_suppl, abstract TPS2661). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GSK3901961 | GSK-3901961|GSK 3901961 | GSK3901961 are autologous T lymphocytes engineered to express the CD8-alpha chain and a T-cell receptor targeting NY-ESO-1, which may lead to cytotoxic T-cell-mediated killing of NY-ESO-1-overexpressing tumor cells (J Clin Oncol 39, no. 15_suppl, abstract TPS2661). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04526509 | Phase I | Cyclophosphamide + Fludarabine GSK3901961 GSK3845097 | Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors | Terminated | USA | SWE | NLD | DEU | CAN | AUS | 0 |